Suman Malempati

Associate Professor

  • 766 Citations
  • 13 h-Index
20052019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Suman Malempati is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 8 Similar Profiles
Rhabdomyosarcoma Medicine & Life Sciences
Pediatrics Medicine & Life Sciences
Precursor Cell Lymphoblastic Leukemia-Lymphoma Medicine & Life Sciences
Pemetrexed Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Embryonal Rhabdomyosarcoma Medicine & Life Sciences
Langerhans Cell Histiocytosis Medicine & Life Sciences
Bone Marrow Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2005 2019

  • 766 Citations
  • 13 h-Index
  • 24 Article
  • 2 Chapter

Phase II trial of the glycoprotein non-metastatic B-targeted antibody–drug conjugate, glembatumumab vedotin (CDX-011), in recurrent osteosarcoma AOST1521: A report from the Children's Oncology Group

Kopp, L. M., Malempati, S., Krailo, M., Gao, Y., Buxton, A., Weigel, B. J., Hawthorne, T., Crowley, E., Moscow, J. A., Reid, J. M., Villalobos, V., Randall, R. L., Gorlick, R. & Janeway, K. A., Nov 2019, In : European Journal of Cancer. 121, p. 177-183 7 p.

Research output: Contribution to journalArticle

Osteosarcoma
Glycoproteins
glembatumumab vedotin
Exanthema
Microtubules

Langerhans cell histiocytosis

Henry, M. M., Malempati, S. & Nicholson, H. S., Nov 19 2018, Wintrobe's Clinical Hematology: Fourteenth Edition. Wolters Kluwer Health Pharma Solutions (Europe) Ltd, p. 4039-4078 40 p.

Research output: Chapter in Book/Report/Conference proceedingChapter

Langerhans Cell Histiocytosis
3 Citations (Scopus)

The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children’s Oncology Group

Malempati, S., Weigel, B. J., Chi, Y. Y., Tian, J., Anderson, J. R., Parham, D. M., Teot, L. A., Rodeberg, D. A., Yock, T. I., Shulkin, B. L., Spunt, S. L., Meyer, W. H. & Hawkins, D. S., Jan 1 2018, (Accepted/In press) In : Cancer.

Research output: Contribution to journalArticle

temozolomide
Rhabdomyosarcoma
Drug Therapy
irinotecan
Vincristine
3 Citations (Scopus)

Navigating your career path in pediatric hematology/oncology: On and off the beaten track

Zweidler-McKay, P. A., Hogan, M. J. S., Jubran, R., Black, V., Casillas, J., Harper, J., Malempati, S., Margolin, J., Felgenhauer, J., Sakamoto, K. M., Franklin, J., Shah, M., Seibel, N., Buchanan, G., Vaiselbuh, S. R., Hastings, C., Hilden, J. & Stork, L., Oct 1 2016, In : Pediatric Blood and Cancer. 63, 10, p. 1723-1730 8 p.

Research output: Contribution to journalArticle

5 Citations (Scopus)

A patient-derived xenograft model of parameningeal embryonal rhabdomyosarcoma for preclinical studies

Hooper, J. E., Cantor, E. L., Ehlen, M. S., Banerjee, A., Malempati, S., Stenzel, P., Woltjer, R. R., Gandour-Edwards, R., Goodwin, N. C., Yang, Y., Kaur, P., Bult, C. J., Airhart, S. D. & Keller, C., 2015, In : Sarcoma. 2015, 826124.

Research output: Contribution to journalArticle

Embryonal Rhabdomyosarcoma
Heterografts
Neoplasms
Autopsy
Phosphotransferases